First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies

被引：0
|
作者：
Smith, J. [1 ]
Urosevic, J. [1 ]
Moore, S. [1 ]
Magiera, L. [1 ]
Bradshaw, L. [1 ]
Gianni, D. [2 ]
Srinivasan, B. [2 ]
Debreczeni, J. [2 ]
Stubbs, C. [2 ]
Vazquez-Chantada, M. [2 ]
Hong, T. [3 ]
Cronin, A. [1 ]
Khan, K. [1 ]
Wiseman, E. [1 ]
Ferguson, D. [3 ]
Lynch, J. [1 ]
Chan, H. M. [3 ]
Critchlow, S. [1 ]
Fawell, S. [3 ]
Dean, E. [1 ]
机构：
[1] AstraZeneca, Res & Early Dev Oncol R&D, Cambridge, England
[2] AstraZeneca, Discovery Sci Biopharmaceut R&D, Cambridge, England
[3] AstraZeneca, Res & Early Dev Oncol R&D, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB134
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 32 条
  • [1] PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.
    Spira, Alexander I.
    Lau, James
    Hattersley, Maureen M.
    Aronson, Boaz E.
    Peters, Jane
    Soo-Hoo, Yee
    Sawant, Aarti
    Loizou, Joanna
    Smith, Claire
    Dean, Emma
    Postel-Vinay, Sophie
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] iscovery and characterization of an MTA-cooperative and brain-penetrant PRMT5 inhibitor
    Pan, Welling
    Wang, Hui
    Qi, Fangfei
    Deng, Haibing
    Yang, Fei
    Yu, Hongping
    Xu, Yao-Chang
    Chen, Zhui
    Ying, Haiyan
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [3] Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
    Cottrell, Kevin M.
    Briggs, Kimberly J.
    Tsai, Alice
    Tonini, Matthew R.
    Whittington, Douglas A.
    Gong, Shanzhong
    Liang, Colin
    Mccarren, Patrick
    Zhang, Minjie
    Zhang, Wenhai
    Huang, Alan
    Maxwell, John P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (05) : 5097 - 5119
  • [4] Discovery of highly selective novel MTA-cooperative PRMT5 inhibitors for the treatment of cancers
    Wu, Wen-Lian
    Hu, Taishan
    Deng, Zhilin
    Li, Honghai
    Shen, Quanrong
    Zhang, Lei
    Ma, Xiaochu
    Sun, Peihua
    Cheng, Cindy
    Liu, Fang
    Chen, Xin
    Hua, Ye
    Huang, Bryan
    CANCER RESEARCH, 2024, 84 (06)
  • [5] HSK41959-2: An oral MTA-cooperative PRMT5 inhibitor for MTAP deleted cancer
    Yan, Pangke
    Wang, Ju
    Qian, Meilin
    Yu, Xiaojuan
    Li, Yao
    Zhang, Haoliang
    Tao, Lihua
    Kou, Rui
    Hu, Teng
    Tang, Pingming
    Dong, Hongjiao
    Wu, Aipin
    He, Maotao
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
    Pettus, Liping H.
    Bourbeau, Matthew
    Tamayo, Nuria A.
    Amegadzie, Albert
    Beylkin, Diane
    Booker, Shon K.
    Butler, John
    Frohn, Michael J.
    Kaller, Matthew R.
    Kohn, Todd
    Lanman, Brian A.
    Li, Kexue
    Liu, Qingyian
    Ma, Vu
    Medina, Jose
    Minatti, Ana E.
    Lopez, Patricia
    Manoni, Francesco
    Pickrell, Alex
    Weires, Nicholas
    Andersson, Jan
    Cowland, Sanne
    Glad, Sanne
    Sarvary, Ian
    Vestergaard, Mikkel
    Li, Weikun
    Ghimire-Rijal, Sudipa
    Mardirossian, Narbe
    Mukund, Susmith
    Chen, Qing
    Lo, Mei-Chu
    Ngo, Rachel
    Khetan, Jawahar
    Madoux, Franck
    Sanders, Christiana
    Sharma, Pooja
    Wang, Paul
    Bruenner, Bernd
    Mccloud, Stuart
    Ponce, Manuel
    Soto, Marcus
    Wahlstrom, Jan
    Xie, Fang
    Yang, Yajing
    Liu, Siyuan
    Tan, Hong
    Policheni, Antonia
    Caenepeel, Sean
    Slemmons, Katherine K.
    Belmontes, Brian
    JOURNAL OF MEDICINAL CHEMISTRY, 2025,
  • [7] PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
    Kim, Tae Min
    Lewis, Katharine L.
    Alderuccio, Juan Pablo
    Lee, Hun Ju
    Derenzini, Enrico
    Zinzani, Pier Luigi
    Ladetto, Marco
    Ghesquieres, Herve
    Phillips, Elizabeth H.
    Lemonnier, Francois
    Morschhauser, Franck
    Balari, Ana Sureda
    Izquierdo, Antonia Rodriguez
    Borchmann, Peter
    Weinstock, Matthew
    Svoboda, Jakub
    Dean, Emma
    Urosevic, Jelena
    Meyer, Stefanie
    Chen, Robert
    Olsson, Richard
    Beyfuss, Kaitlyn
    Collins, Graham P.
    BLOOD, 2024, 144 : 16742 - 16743
  • [8] Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor
    Liang, Jianglin Colin
    Li, Hongming
    Cottrell, Kevin M.
    Liu, Yong
    Maxwell, John P.
    Xin, Zhengyang
    Anzalone, Luigi
    Ronn, Magnus
    Palmieri Jr, Michael A.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2025, 29 (03) : 946 - 952
  • [9] Biochemical characterization of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers
    Zhang, W.
    Gong, S.
    Cottrell, K.
    Briggs, K.
    Tonini, M.
    Gu, L.
    Whittington, D.
    Yuan, H.
    Gotur, D.
    Jahic, H.
    Huang, A.
    Maxwell, J.
    Mallender, W.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S26 - S26
  • [10] Preclinical characterization of ABSK131, a potential best-in-class MTA-cooperative PRMT5 inhibitor
    Pan, W.
    Wang, H.
    Qi, F.
    Deng, H.
    Yu, H.
    Xu, Y. C.
    Chen, Z.
    Ying, H.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S17 - S18
1234